Kathryn McParlane
Acute Care · Moon Township, PANPI 1649252594
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 81.3% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $7,199 and has fallen 98.7% since, to $95 in 2025. Among acute care clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 280 payments — averaging $76.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$17K
- AbbVie$870
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$633
- Johnson & Johnson$533
- Daiichi Sankyo Inc.$442
- Takeda Pharmaceuticals U.S.A., Inc.$310
- plus $1K from 14 others
What the payments were for
- Speaking & faculty fees$11,80055%
- Travel & lodging$4,75922%
- Food & beverage$4,79422%
- Education$510%
- Gifts$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 52 | $17,471 |
| AbbVie | 40 | $870 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 59 | $633 |
| Johnson & Johnson | 41 | $533 |
| Daiichi Sankyo Inc. | 14 | $442 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $310 |
| Janssen Scientific Affairs, LLC | 2 | $181 |
| Braintree Laboratories, Inc. | 18 | $155 |
| Sanofi | 4 | $129 |
| QOL Medical, LLC | 5 | $123 |
| Regeneron Healthcare Solutions, Inc. | 4 | $118 |
| Ardelyx, Inc. | 4 | $110 |
| Bristol Myers Squibb | 7 | $108 |
| Intercept Pharmaceuticals, Inc. | 4 | $94 |
| Merck | 4 | $74 |
| Ironwood Pharmaceuticals, Inc | 3 | $55 |
| Amgen | 1 | $31 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Organon | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$12,592
- INJECTAFER$223
- PLENVU$120
- VRAYLAR$114
How this compares
$21,483 in reported general payments places this provider in the 95th percentile of 872 acute care providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cholestyramine LightCholestyramine | 12 | $1,121 |
| Omeprazole | 25 | $311 |
| Pantoprazole Sodium | 16 | $243 |
| Famotidine | 11 | $236 |
Paid to pharmacies, not to this prescriber.
Other acute care in Moon Township
- Kristi MontrellaAltoona$111K
- Kathryn GreenPhiladelphia$92K
- Caroline PratzPhiladelphia$77K
- Donna KinzlerPittsburgh$25K
- Lisa JohnsonPottstown$25K
- Rebecca MarcantuonoPhiladelphia$17K
- Stephanie TothPhiladelphia$17K
- Kevin HaganAbington$17K
- Rachel ChristyButler$14K
- Kelly ApplebaumAbington$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.